Ozempic Lawsuits: Possible Compensation for Damages

Ozempic (semaglutide) represents a glucagon-like peptide-1 (GLP-1) receptor agonist medication that the FDA approved in December 2017 for managing type 2 diabetes.

While initially developed for blood sugar control, this weight management drug and similar medications have gained massive popularity for weight loss purposes, leading to widespread adoption across the United States.

Ozempic (semaglutide) injection 0.5 mg or 1 mg was approved by the FDA in December 2017, and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

This rapid expansion in use (with nearly 12% of Americans now having tried GLP-1 medications) has brought with it concerning reports of severe side effects that manufacturers allegedly failed to adequately disclose, forming the basis of thousands of lawsuits now consolidated in federal court.

What Is Ozempic and How Does It Work?

Ozempic operates as a prescription medication designed to mimic the naturally occurring GLP-1 hormone that your body produces after food intake.

The FDA approved this once-weekly injection on December 5, 2017, specifically for adults with type 2 diabetes to help regulate blood sugar levels when combined with diet and exercise.

Ozempic is a glucagon-like peptide-1 (GLP-1) analog for the treatment type 2 diabetes.

The medication’s unique molecular structure allows it to remain active in the bloodstream for approximately one week, making it convenient for patients who prefer weekly rather than daily injections.

GLP-1 medications like Ozempic affect multiple body systems through these primary mechanisms:

• Stimulating insulin secretion: When blood glucose levels rise after meals, Ozempic triggers the pancreas to release insulin in a glucose-dependent manner, helping cells absorb sugar from the bloodstream
• Decreasing glucagon release: The medication suppresses the hormone glucagon, which normally signals the liver to release stored glucose, thereby preventing unnecessary increases in blood sugar
• Slowing gastric emptying: By delaying how quickly food leaves the stomach and enters the small intestine, Ozempic prolongs feelings of fullness and reduces post-meal blood sugar spikes – this same mechanism (which healthcare providers now recognize) has been linked to severe complications in litigation
• Affecting brain receptors: The medication acts on GLP-1 receptors in brain regions that control appetite and satiety, contributing to substantial weight loss effects that led to its widespread off-label use

The FDA approval in December 2017 marked the beginning of what would become one of the fastest-growing pharmaceutical markets in recent history.

Clinical trials demonstrated that Ozempic produced statistically notable reductions in hemoglobin A1c levels compared to placebo and other diabetes medications, with the added benefit of body weight reduction as a secondary outcome.

This weight loss effect, though initially positioned as a side benefit for diabetes patients, quickly became the primary reason many people sought prescriptions.

By August 2025, research from the RAND American Life Panel showed that approximately 11.8% of American adults (nearly 1 in 8 people) had used GLP-1 medications at least once, marking a dramatic increase in adoption.

Novo Nordisk later capitalized on these weight loss effects by releasing Wegovy in June 2021, which contains higher doses of the same semaglutide molecule but carries FDA approval specifically for chronic weight management.

This widespread use of these popular weight loss drugs, both for approved diabetes treatment and off-label weight loss, has now resulted in thousands of patients reporting severe gastrointestinal injuries and vision loss, conditions that many allege were not adequately disclosed on warning labels when they began treatment.

Other GLP-1 Medications Involved in Litigation

The federal multidistrict litigation consolidated as MDL 3094 encompasses multiple GLP-1 receptor agonist medications beyond just Ozempic, reflecting the class-wide nature of the alleged injuries and inadequate warnings.

This class of medications includes:

• Ozempic, Wegovy, and Rybelsus (produced by the Novo Nordisk defendants); and
• Trulicity and Mounjaro (produced by Eli Lilly and Company).

These medications share similar mechanisms of action (all activate GLP-1 receptors to slow gastric emptying and regulate blood sugar) which forms the basis for their consolidation in a single litigation proceeding.

While Ozempic and other GLP-1 medications contain different active molecules and carry distinct brand names, they allegedly cause the same types of severe gastrointestinal complications.

Federal courts have consolidated cases involving these GLP-1 receptor agonist medications:

• Wegovy (semaglutide): Manufactured by Novo Nordisk and approved by the FDA in June 2021 specifically for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition; contains higher doses of semaglutide (up to 2.4 mg weekly) compared to Ozempic’s maximum 2 mg dose
• Rybelsus (oral semaglutide): Also from Novo Nordisk, this represents the first oral GLP-1 medication approved for type 2 diabetes in September 2019; despite being taken as a daily pill rather than injection, it contains the same active ingredient and allegedly carries similar risks
• Mounjaro (tirzepatide): Manufactured by Eli Lilly and approved in May 2022, this medication works as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, offering enhanced blood sugar control and weight loss effects but also allegedly causing severe gastrointestinal injuries similar to semaglutide products
• Trulicity (dulaglutide): Eli Lilly’s once-weekly GLP-1 injection approved in 2014 for type 2 diabetes; while older than Ozempic, it operates through the same gastric-slowing mechanism and faces allegations of inadequate warnings about gastroparesis and related complications
• Saxenda (liraglutide): A Novo Nordisk product approved in 2014 for chronic weight management that requires daily rather than weekly injections; the Judicial Panel on Multidistrict Litigation added Saxenda to MDL 3094 in December 2024, expanding the scope to include this earlier-generation GLP-1 medication

The consolidation of these medications into a single MDL proceedings streamlines the litigation process while allowing each plaintiff to maintain their individual claim for damages.

All five medications share common allegations that their manufacturers knew or should have known about the risks of gastroparesis, intestinal obstruction, and other severe gastrointestinal injuries, yet failed to provide adequate warnings to patients and physicians.

The pharmaceutical companies’ extensive marketing of these drugs (with Novo Nordisk and Eli Lilly commanding market dominance and generating billions in annual revenue) created widespread exposure among both diabetes patients and those seeking weight loss.

The judicial panel concluded that grouping these medications together serves the interests of judicial efficiency because they involve overlapping questions about corporate knowledge, warning label adequacy, and the causal relationship between GLP-1 receptor activation and severe gastric complications.

This multi-defendant, multi-drug approach reflects the systemic nature of the alleged failures to warn, as opposed to isolated problems with a single product.

If you or a loved one developed gastroparesis, intestinal blockages, or other severe gastrointestinal injuries after taking Ozempic, Wegovy, Mounjaro, or similar GLP-1 medications, you may be entitled to compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine if you qualify to file an Ozempic lawsuit today.

While pharmaceutical companies marketed GLP-1 medications as effective treatments for diabetes and weight management, thousands of patients have reported severe adverse effects that allegedly were not adequately disclosed before they began treatment.

These documented medical conditions go far beyond the mild nausea and digestive discomfort commonly associated with these drugs, instead representing life-altering complications requiring hospitalization, surgical intervention, and ongoing medical management.

Nearly 12% of Americans have used GLP-1 drugs for weight loss.

Among those who have used GLP-1 drugs, about half report they have experienced nausea and about one-third experienced diarrhea.

The severity of injuries now forming the basis of litigation demonstrates why plaintiffs allege manufacturers failed to provide adequate warnings about risks that extend well beyond temporary side effects.

Gastrointestinal Injuries and Complications

Gastrointestinal injuries represent the primary focus of MDL 3094 litigation, with thousands of plaintiffs alleging that GLP-1 medications caused severe and sometimes permanent damage to their digestive systems.

Each lawsuit contains substantially similar allegations about GLP-1 RAs and their alleged propensity to cause gastrointestinal injuries.

The FDA has received adverse event reports of gastrointestinal disorders associated with semaglutide medications, reflecting widespread problems that many patients and physicians claim were not adequately communicated through warning labels when treatment began.

Plaintiffs in the litigation report experiencing these specific digestive system complications:

• Gastroparesis (stomach paralysis): The most common injury alleged in lawsuits, this condition involves partial or complete paralysis of stomach muscles that prevents proper digestion and can persist even after discontinuing medication
• Ileus (intestinal blockage): Added to FDA warning labels in September 2023 after post-marketing reports, this condition stops intestinal movement and can lead to life-threatening complications including infection and tissue death
• Intestinal obstruction and pseudo-obstruction: Physical or functional blockages requiring emergency hospitalization and often surgical intervention to prevent bowel perforation
• Chronic severe symptoms: Persistent vomiting, uncontrollable nausea, dangerous dehydration requiring IV fluids, and electrolyte imbalances necessitating repeated emergency department visits

The FDA’s decision to update warning labels demonstrates growing concern about these complications.

In January 2025, regulators added warnings about severe gastrointestinal adverse reactions, acknowledging that the slowed gastric emptying mechanism can lead to far more serious consequences than initially disclosed.

Many plaintiffs report experiencing symptoms so debilitating that they required hospitalization, feeding tubes, or permanent dietary modifications – injuries they allege should have been clearly communicated before they filled their first prescription.

If you experienced severe vomiting, chronic nausea, dangerous dehydration, or stomach paralysis after using Ozempic or Wegovy, you may have grounds for legal action.

Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others filing Ozempic lawsuits today.

Vision Loss and NAION Concerns

Non-arteritic anterior ischemic optic neuropathy (NAION) has emerged as a particularly devastating injury linked to GLP-1 medications, representing the second leading cause of optic nerve-related blindness in adults.

Patients with diabetes who had been prescribed semaglutide were more than four times more likely to be diagnosed with NAION.

Those who were prescribed this drug and were overweight or had obesity were more than seven times more likely to get the diagnosis.

This July 2024 study from Harvard Medical School and Massachusetts Eye and Ear triggered serious concerns among ophthalmologists and patients about risks that remain inadequately disclosed on current warning labels.

Research has identified these alarming vision-related risks associated with GLP-1 medications:

• Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration
• Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk
• European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators
• Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability

The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication.

Ophthalmologists describe the condition as similar to a “stroke” affecting the optic nerve, where blocked blood flow causes tissue death and permanent vision impairment.

Despite mounting evidence of this connection, Novo Nordisk’s current warning labels for Ozempic and Wegovy do not list NAION as a specific risk, mentioning only general “vision changes” among potential risks – a disclosure many patients and legal experts argue falls far short of adequate warning about permanent blindness.

If you suffered sudden vision loss, blind spots, or were diagnosed with NAION after taking Ozempic, Wegovy, or other GLP-1 medications, you may be eligible to seek financial compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to file a GLP-1 lawsuit today.

Additional Reported Adverse Effects

Beyond gastroparesis and vision loss, patients have reported numerous other serious adverse effects that have led to FDA warning label updates as evidence accumulated.

The FDA has repeatedly updated Ozempic’s warning label as evidence of serious side effects accumulated: March 2022 Gallbladder disease was added; September 2023 FDA added ileus warnings; November 2024 Pulmonary aspiration during anesthesia was added.

This timeline of progressive label modifications raises questions about Ozempic’s warning label adequacy, what manufacturers knew, when they knew it, and whether early patients received adequate warnings before these updates occurred.

FDA warning label updates have progressively acknowledged these additional serious complications:

• Gallbladder disease (March 2022): Increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) requiring surgical removal, with many patients developing symptoms severe enough to necessitate emergency cholecystectomy procedures
• Intestinal obstruction and ileus (September 2023): FDA acknowledged reports of intestinal blockages that halt normal bowel movement, potentially leading to bowel perforation, sepsis, and death without emergency intervention
• Pulmonary aspiration during anesthesia (November 2024): Recognition that delayed gastric emptying causes patients to retain food in stomachs far longer than expected, creating aspiration risks when undergoing procedures requiring sedation or general anesthesia
• Severe gastrointestinal adverse reactions (January 2025): FDA added warnings about serious GI events including severe gastroparesis symptoms and complications requiring hospitalization or surgical intervention

The fact that patients who began treatment in 2017, 2018, or 2019 received medications without warnings about ileus, pulmonary aspiration, or severe gastroparesis demonstrates the alleged failure to provide timely and adequate disclosures about serious complications that medical science now clearly links to these medications.

Stomach paralysis (medically termed gastroparesis) represents the most frequently reported severe injury among patients taking GLP-1 medications.

People taking GLP-1 drugs like those being prescribed Ozempic were 66% more likely to be diagnosed with gastroparesis, with 0.53% of patients diagnosed – about 750 out of nearly 150,000 patients.

Thousands allege they developed severe, sometimes permanent stomach dysfunction altering their ability to eat, work, and live normally.

What Is Gastroparesis and How Does It Develop?

Gastroparesis occurs when stomach muscles fail to contract properly, causing food to remain far longer than normal despite no physical obstruction.

Gastroparesis is delayed gastric emptying in the absence of mechanical obstruction, lasting at least 3 months, causing nausea, vomiting, bloating, early satiety, and abdominal pain.

Nerve damage affecting stomach muscles or direct muscle damage impairs contractions needed to move food through the pyloric valve.

Medical experts have identified four primary ways GLP-1 drugs trigger stomach paralysis:

• Excessive GLP-1 receptor activation: Continuous stimulation causes extreme delays progressing to paralysis of stomach muscle function
• Disrupted stomach pacemaker cells: GLP-1 drugs affect specialized cells generating electrical rhythms, causing gastric arrhythmia
• Impaired pyloric sphincter function: Prevents proper valve relaxation between stomach and small intestine, creating functional obstruction
• Accumulation effects: Duration of use correlates with severity, as prolonged exposure causes progressive nerve dysfunction

Healthy individuals empty approximately 40-90% of meals within one hour, retaining less than 10% after four hours.

Gastroparesis patients retain over 60% at two hours or over 10% at four hours, creating conditions where food ferments, forms solid bezoar masses, and prevents nutrition absorption.

Symptoms and Diagnosis Methods

Patients experience symptoms beginning as ordinary side effects but progressing to severe complications requiring hospitalization, often persisting despite dietary modifications.

Patients experiencing gastroparesis commonly report the following debilitating symptoms:

• Severe nausea and vomiting: Multiple daily episodes, unable to keep down liquids, leading to dangerous dehydration requiring emergency IV fluids
• Extreme early satiety: Feeling full after few bites, with food “stuck” in throat persisting hours
• Chronic abdominal pain and bloating: Persistent upper abdomen distention interfering with daily activities
• Dangerous weight loss: Inability to consume adequate calories causing vitamin deficiencies, muscle wasting, requiring feeding tubes
• Blood sugar fluctuations: Unpredictable glucose with nighttime lows followed by morning highs

Diagnosing requires specific testing to measure gastric emptying.

Gastric emptying scintigraphy is the gold standard – patients eat meals with radioactive tracer, undergoing imaging at one, two, and four hours, with gastroparesis confirmed if more than 60% retention at two hours or more than 10% at four hours.

Providers first perform upper endoscopy ruling out mechanical obstructions.

Additional tools include wireless motility capsules, antroduodenal manometry, and gastric ultrasonography.

If you’ve experienced persistent vomiting, inability to eat, or severe stomach pain after taking Ozempic or Wegovy, TruLaw can connect you with experienced attorneys who can help you gather medical records and understand the medical and legal intricacies of GLP-1-related gastroparesis claims.

Our network has helped patients document their injuries and pursue compensation for ongoing medical care.

Is Gastroparesis Reversible After Stopping Ozempic?

Whether GLP-1-induced gastroparesis resolves after discontinuing medication remains contentious, with conflicting evidence about permanence.

A 2021 medical study stated medication-induced gastroparesis is reversible and discontinuing is generally curative, with repeat studies showing improvement and resolution.

This suggests stopping GLP-1 drugs allows stomach function to return as medication clears over four to five weeks.

Real-world patient experiences contradict this optimism.

Media reports describe women with stomach paralysis, with severe effects continuing at least a year after discontinuing in two of three cases.

Lawsuits describe individuals hospitalized months, placed on permanent feeding tubes, or requiring gastric bypass surgery despite cessation.

Some with no prior gastrointestinal disease developed apparently permanent dysfunction.

Several variables may influence whether stomach function returns after stopping GLP-1 medications:

• Duration and dosage: Longer exposure and higher doses may increase permanent damage likelihood
• Pre-existing vulnerabilities: Patients with borderline slow emptying, prior surgery, diabetes, or autoimmune conditions may experience irreversible damage
• Individual metabolic factors: Variations in semaglutide metabolism may explain different outcomes
• Timing of intervention: Immediate discontinuation upon symptoms may improve recovery prospects

The pharmaceutical industry’s failure to conduct long-term outcome studies has left patients and the medical community without guidance.

This uncertainty forms a central litigation allegation – manufacturers rushed medications to market and promoted them for off-label weight loss without adequately studying or disclosing potential permanent digestive damage.

If you continue experiencing severe stomach paralysis, persistent vomiting, or inability to eat normally even after discontinuing Ozempic or Wegovy, you may have a valid legal claim.

Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to pursue an Ozempic injury lawsuit today.

Non-arteritic anterior ischemic optic neuropathy represents one of the most devastating injuries linked to GLP-1 medications, causing sudden, irreversible blindness that no medical treatment can reverse.

A July 2024 Harvard study found diabetes patients prescribed semaglutide were over four times likely to develop NAION, while those prescribed it for weight loss were over seven times likely to develop this condition.

The permanent nature distinguishes NAION from other GLP-1 complications, leaving patients facing lifelong disability from an injury they allege manufacturers failed to adequately disclose.

What Is NAION and How Does It Cause Blindness?

NAION occurs when blood flow to the optic nerve becomes disrupted, causing nerve tissue death similar to how a stroke damages brain tissue – this “eye stroke” results in permanent vision destruction with no restoration possibility.

NAION is the most common optic neuropathy in adults over 50, caused by hypoperfusion of short posterior ciliary arteries supplying the optic nerve, inducing swelling that creates compartment syndrome compressing neighboring axons, resulting in ganglion cell death.

The condition strikes without warning, often discovered upon waking.

The process through which NAION destroys vision involves these sequential pathological events:

• Sudden blood supply disruption: Short posterior ciliary arteries feeding the optic nerve become blocked or experience severe flow reduction, starving nerve tissue
• Immediate nerve tissue death: Ischemic damage kills optic nerve cells within hours – once dead, these neurons cannot regenerate
• Compartment syndrome: Initial swelling compresses remaining healthy nerve fibers in the confined scleral canal space, creating cascading damage
• Permanent structural changes: The optic nerve develops atrophy, with dead tissue replaced by glial scarring unable to transmit visual signals

NAION commonly affects individuals with “crowded optic discs” or “disc at risk,” where cup-to-disc ratio measures 0.2 or less.

Up to 97% of NAION patients have small optic discs with small or absent cups, representing the strongest risk factor.

Diabetes itself increases NAION risk, creating particularly dangerous situations when patients take GLP-1 medications that multiply already elevated baseline risk.

Research Linking GLP-1 Medications to NAION

Multiple large-scale studies published in 2024-2025 documented alarming associations between semaglutide and dramatically elevated NAION rates.

A Danish study examining 424,152 persons with type 2 diabetes found patients exposed to weekly semaglutide had 2.19 times higher NAION risk, with Denmark’s annual first-time NAION cases rising from 67.6 to 148 since Ozempic’s 2018 introduction.

This population-level increase suggests widespread adoption directly contributed to surging blinding events.

The original Mass Eye and Ear study found even more dramatic risk elevations.

Among patients prescribed semaglutide for diabetes, the hazard ratio was 4.28, while overweight or obese patients showed 7.64, with cumulative NAION incidence reaching 6.7% over 36 months compared to 0.8% for non-GLP-1 medications.

These statistics indicate approximately 6 to 7 out of every 100 patients taking semaglutide for weight loss over three years will suffer permanent vision loss – a risk many allege they were never warned about.

In June 2025, the European Medicines Agency officially recognized NAION as a very rare side effect of semaglutide after reviewing all data, concluding it may affect up to 1 in 10,000 people and recommending product information updates.

This regulatory acknowledgment validates concerns that manufacturers should have disclosed this risk earlier, given the condition’s catastrophic and permanent nature.

If you’ve experienced sudden vision loss, blind spots, or difficulty seeing after taking Ozempic, Wegovy, or similar medications, TruLaw can help you explore your legal options.

Our team works with medical experts who understand NAION and can evaluate whether your vision loss qualifies for compensation.

Living With Permanent Vision Loss From NAION

Patients who develop NAION face lifelong consequences that no medical intervention can reverse, as current science offers no effective treatment once optic nerve tissue has died.

Multiple clinical trials studying over a dozen therapies failed to show improvement in visual outcomes for NAION patients, with surgical interventions showing no benefit and potentially causing harm.

The best ophthalmologists can offer is monitoring to ensure the condition doesn’t affect the second eye, which carries approximately 30% lifetime risk.

Patients face these permanent life-altering consequences from NAION-related blindness:

• Sudden blindness in affected eye: Most experience dense altitudinal visual field loss affecting top or bottom half, with some suffering complete blindness
• Inability to drive or work: Vision loss severe enough to disqualify from driving and render many occupations impossible
• Constant risk to fellow eye: Living with approximately 15% risk over five years that the second eye will suffer identical fate
• No restorative treatment options: Unlike cataracts, NAION leaves patients with zero medical solutions for recovery

Permanent disability from NAION has made these injuries central to litigation.

Patients argue they would never have risked blindness for weight loss had labels disclosed this possibility.

Manufacturers continuing aggressive marketing while studies linking drugs to vision loss accumulated forms a key allegation – prioritizing profits over safety by failing to update warnings as NAION evidence emerged.

If you developed permanent blindness, irreversible vision loss, or NAION after taking Ozempic or similar weight loss medications, you may be entitled to substantial compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine if you qualify to file an NAION lawsuit today.

Thousands of patients have filed lawsuits involving Ozempic and other GLP-1 medications against Novo Nordisk and Eli Lilly alleging these pharmaceutical giants knew or should have known about severe gastrointestinal and vision complications yet failed to provide adequate warnings, prioritizing profits from blockbuster drug sales over patient safety.

The central legal theory driving these cases stems from product liability law’s “failure to warn” doctrine, which holds manufacturers responsible for injuries when they fail to provide adequate warnings about known or knowable risks.

Plaintiffs argue that mounting medical evidence about gastroparesis, intestinal obstruction, and NAION vision loss should have prompted immediate and comprehensive warning label updates – not the reactive, incremental modifications that only occurred after thousands of patients suffered these exact injuries.

Failure to Adequately Warn Patients About Known Risks

The master complaint filed in MDL 3094 alleges that Novo Nordisk and Eli Lilly knew or should have known about the severe gastroparesis and vision loss risks associated with their GLP-1 medications but failed to provide adequate warnings on product labels, marketing materials, or prescribing information.

Plaintiffs point to pre-approval clinical trials and post-marketing adverse event reports that accumulated evidence of severe gastrointestinal complications years before manufacturers updated warning labels to reflect these serious risks.

The timeline of label updates reveals what plaintiffs characterize as inexcusable delays between knowledge and disclosure.

When Ozempic received FDA approval in December 2017, its labeling mentioned only mild gastrointestinal side effects like nausea and vomiting – common and generally temporary reactions to GLP-1 medications.

Yet by September 2023, the FDA required adding ileus warnings after post-marketing reports documented severe intestinal blockages.

This six-year gap between initial approval and ileus warnings represents thousands of patients who allegedly took these medications without adequate information about potentially life-threatening complications.

The vision loss connection demonstrates an even more troubling pattern.

Despite Harvard Medical School research published in July 2024 showing diabetes patients prescribed semaglutide faced over four times higher NAION risk (and weight loss patients faced over seven times higher risk) Novo Nordisk’s current Ozempic and Wegovy labels still mention only generic “vision changes” without specifically identifying NAION or permanent blindness as known risks.

This alleged failure to update warnings despite mounting scientific evidence forms the cornerstone of failure-to-warn claims, with plaintiffs arguing manufacturers prioritized continued drug sales over patient safety by minimizing disclosures about permanent, life-altering injuries.

Allegations of Deceptive Marketing and Profit Prioritization

Beyond inadequate warnings, plaintiffs allege Novo Nordisk engaged in deceptive marketing practices that created unrealistic expectations while downplaying serious risks.

The master complaint claims defendants “intentionally targeted the American population,” understanding the vast financial potential of weight-loss medication markets, spending untold millions to get medications covered under insurance even before GLP-1 RAs received weight-loss approval.

The litigation alleges manufacturers set out to create and expand markets by advocating for obesity classification as a disease, thereby justifying pharmaceutical intervention and insurance coverage.

This aggressive marketing occurred while manufacturers allegedly knew about severe complications.

Plaintiffs contend that Novo Nordisk promoted Ozempic and Wegovy as miracle weight-loss drugs through massive advertising campaigns (including ubiquitous television commercials and print advertisements) while minimizing or omitting warnings about stomach paralysis, intestinal obstruction, and permanent blindness.

The financial incentives were enormous: GLP-1 medications generated billions annually, creating powerful motivation to increase prescriptions rather than conduct thorough safety investigations or provide complete risk disclosures.

If you’ve suffered serious injuries after taking Ozempic, Wegovy, or similar medications and believe you weren’t adequately warned about risks, TruLaw can evaluate whether you have grounds for legal action.

Our network of experienced attorneys understands the failure to warn legal standards and can help you seek accountability from manufacturers who prioritized profits over patient safety.

Pattern of Inadequate Response to Safety Signals

The progressive timeline of FDA warning label updates demonstrates what plaintiffs allege represents a systemic failure by manufacturers to act quickly when safety concerns emerged.

March 2022 saw gallbladder disease added to labels, September 2023 brought ileus warnings, and November 2024 added pulmonary aspiration risks – each update coming only after patients suffered these exact injuries.

This reactive pattern forms a central litigation theme: that manufacturers waited for definitive proof of harm through patient injuries rather than exercising caution when early warning signals appeared.

Plaintiffs who began treatment in 2017, 2018, or 2019 received medications without warnings about conditions now recognized as medication-related.

These early users argue they served as unwitting test subjects, suffering permanent injuries that manufacturers should have predicted and disclosed.

The litigation seeks to hold pharmaceutical companies accountable for this alleged pattern through Ozempic gastroparesis lawsuits and similar claims, demanding compensation for medical expenses, lost wages, pain and suffering, and permanent disabilities caused by injuries patients allege they would have avoided had they received adequate warnings.

If you suffered serious health complications after taking Ozempic, Wegovy, Mounjaro, or Trulicity and believe you weren’t properly warned about the risks, you may have grounds for legal action.

Contact TruLaw using the chat on this page to receive an instant case evaluation and learn whether you qualify to join others filing Ozempic gastroparesis lawsuits today.

The Ozempic litigation has grown into one of the largest pharmaceutical mass torts in recent history, with numerous Ozempic lawsuits and case numbers accelerating rapidly throughout 2025 as more patients discover connections between their injuries and GLP-1 medications.

As of November 2025, there are 2,914 lawsuits consolidated in MDL 3094 in the Eastern District of Pennsylvania, with over 100 new actions filed in recent months.

This explosive growth of Ozempic lawsuits filed (from 346 cases in mid-2024 to nearly 3,000 by late 2025) reflects increasing awareness as patients linked Ozempic to severe complications and learned about the legal avenues available for seeking compensation.

MDL 3094: Consolidation and Procedural Status

Federal courts consolidated Ozempic, Wegovy, Mounjaro, and related GLP-1 lawsuits into coordinated pretrial proceedings to streamline discovery and ensure consistent rulings on common issues.

Judge Karen Spencer Marston presides over MDL 3094 in the Eastern District of Pennsylvania after the Judicial Panel on Multidistrict Litigation established this consolidation in February 2024.

This centralization allows efficient handling of shared questions about drug mechanisms, warning label adequacy, and corporate knowledge while preserving each plaintiff’s right to individual compensation based on their specific injuries and damages.

The litigation currently remains in the discovery phase, with both sides exchanging documents, relevant medical records, and expert reports.

Expert discovery is scheduled to be completed by March 27, 2026, with motions for summary judgment due April 16, 2026, followed by preparations for the first bellwether trials.

This timeline indicates that the first cases may reach juries by late 2026 or early 2027, though the pace could accelerate if settlement negotiations gain momentum after key pretrial rulings.

The following milestones mark important progress in the consolidated federal litigation:

• Increased evidentiary standards for gastroparesis claims: Courts require plaintiffs alleging gastroparesis to support claims with objective gastric-emptying tests rather than symptoms alone, raising the bar for admissible medical evidence
• Daubert hearings on expert testimony: May 2025 hearings will determine whether plaintiffs’ medical experts can testify about causation – potentially decisive rulings that could strengthen or weaken thousands of claims
• Short-form complaint process adoption: MDL implemented streamlined filing procedures to manage the influx of new cases efficiently while maintaining procedural fairness
• Monthly status conferences throughout 2025: Regular court meetings ensure ongoing case management and coordination as parties work through challenging scientific and legal issues

In September 2025, Judge Marston allowed most plaintiffs’ claims to proceed after denying defendants’ motions to dismiss, including accusations that drugmakers failed to warn about gastrointestinal issues and misrepresented safety.

This ruling established that failure to warn claims have sufficient legal merit to advance toward trial, rejecting Novo Nordisk’s arguments that FDA-approved labeling provided adequate warnings.

Bellwether Trial Selection and Settlement Prospects

Bellwether trials (representative test cases selected to gauge how juries respond to evidence and testimony) will likely begin in early to mid-2026, providing the first courtroom verdicts in this massive litigation.

These early trials serve multiple purposes: they help both sides evaluate case strengths and weaknesses, establish precedents for similar claims, and create pressure for global settlement negotiations if verdicts favor plaintiffs.

Legal analysts estimate total liability could exceed $2 billion, with settlement projections for severe gastroparesis cases ranging from $400,000 to $700,000, while NAION vision loss claims could command over $1 million due to permanent disability.

These estimates account for medical expenses, lost wages, pain and suffering, and potential punitive damages if evidence shows corporate misconduct.

The actual settlement amounts will depend heavily on bellwether trial outcomes and the strength of causation evidence presented by medical experts.

Settlement negotiations have not yet produced global agreements, though discussions may intensify after bellwether verdicts provide concrete data about jury sympathies.

Pharmaceutical companies typically resist early settlements in mass tort litigation, preferring to test their defenses at trial before committing to compensation frameworks.

However, if initial verdicts result in substantial plaintiff awards, manufacturers may calculate that settling thousands of claims proves less expensive than facing repeated trials with unpredictable outcomes.

Please be advised that any projected or estimated settlement amounts mentioned are general estimations and are not guaranteed.

These figures are based on opinions of legal experts based on the nature of the injuries and estimated costs of damages.

They are meant to provide a general idea of what settlement ranges could look like and should not be taken as definitive expectations for your case.

Contact TruLaw using the chat on this page to receive an instant case evaluation.

Parallel State Court Litigation for Vision Loss

While MDL 3094 focuses primarily on gastrointestinal injuries, Ozempic vision loss lawsuits are developing through parallel state court proceedings that may move faster than federal litigation.

Over 30 plaintiffs filed a petition with New Jersey Superior Court in July 2025 requesting multicounty litigation consolidation for NAION vision loss lawsuits.

New Jersey courts may approve this consolidation since Novo Nordisk maintains its U.S.

headquarters in that state, providing logical venue for coordinated state-level proceedings.

State court litigation offers procedural advantages including potentially faster trial schedules and different evidentiary standards compared to federal MDL proceedings.

The European Medicines Agency’s June 2025 recognition of NAION as a very rare side effect of semaglutide strengthens these claims by providing regulatory acknowledgment of the vision loss connection.

If state courts move quickly toward trial, NAION verdicts could emerge before federal gastroparesis cases conclude, potentially influencing settlement dynamics across all GLP-1 litigation.

The bifurcated nature of current litigation (with gastrointestinal claims proceeding federally and vision loss claims advancing through state courts) creates pressure on manufacturers from multiple directions simultaneously, increasing the likelihood that Novo Nordisk and Eli Lilly will eventually pursue comprehensive settlement frameworks addressing both injury types.

Plaintiffs injured by Ozempic and related GLP-1 medications may pursue multiple categories of compensation addressing both financial losses and intangible suffering caused by severe gastrointestinal complications and vision loss.

Settlement amounts vary based on injury severity, medical documentation quality, and causation evidence strength.

Economic Damages: Quantifiable Financial Losses

Economic damages compensate plaintiffs for objectively measurable financial harm resulting from Ozempic-related injuries.

These compensatory awards reimburse actual monetary losses incurred and project future expenses for recovery or lifelong management of permanent conditions.

Compensation for medical costs encompasses both past expenses and projected future treatment needs including ongoing medical treatment:

• Hospital stays and emergency care: Costs for urgent treatment of gastroparesis symptoms, intestinal blockages requiring emergency intervention, or surgical procedures to remove portions of damaged intestines
• Diagnostic testing: Expenses for gastric emptying studies, endoscopic examinations, imaging scans, and vision assessments necessary to diagnose and monitor conditions
• Ongoing treatment and medications: Long-term costs for prescription drugs managing symptoms, nutritional supplementation for malabsorption issues, and regular medical monitoring
• Surgical interventions: Bills for gallbladder removal, intestinal blockage repair, feeding tube placement, or other procedures addressing complications
• Future medical care: Projected lifetime costs for conditions with no cure, including NAION vision loss requiring ongoing ophthalmologic care and gastroparesis demanding permanent dietary modifications

Courts require detailed medical records, itemized billing statements, and expert testimony projecting future care needs.

Plaintiffs must demonstrate clear causation between their Ozempic use and conditions necessitating treatment, with objective diagnostic evidence carrying particular weight after Judge Marston’s August 2025 ruling requiring gastric emptying studies for gastroparesis claims.

If you developed gastroparesis, intestinal blockage, or vision loss after taking Ozempic or related GLP-1 medications, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation that can help you determine if you qualify to file an Ozempic lawsuit today.

Lost wages and diminished earning capacity compensate for income disruptions caused by Ozempic injuries during active treatment and extending into future years if permanent disabilities impair work performance.

Documentation includes pay stubs showing missed work periods, employer statements confirming job impacts, and vocational expert analysis projecting reduced future earnings.

Beyond medical bills, plaintiffs may recover compensation for these financial impacts:

• Transportation expenses: Mileage and travel costs for medical appointments with specialists, emergency room visits, or legal proceedings
• Home modifications: Accessibility improvements for those with permanent disabilities, including vision loss requiring adaptive equipment
• Caregiver costs: Professional or family member assistance during recovery periods when plaintiffs cannot perform daily activities independently

Plaintiffs strengthen their Ozempic claim for economic damages by maintaining detailed records of all expenses from the moment they begin experiencing symptoms.

Non-Economic Damages: Intangible Losses and Suffering

Non-economic damages address the difficult-to-quantify impacts that Ozempic-related injuries impose on plaintiffs’ physical well-being, emotional health, and life satisfaction.

These compensatory awards require juries or settlement negotiators to assign monetary value to subjective experiences of pain, disability, and diminished quality of life.

Pain and suffering compensation recognizes both the acute physical discomfort of Ozempic-related complications and ongoing distress of managing chronic conditions.

Gastroparesis patients endure persistent nausea, severe abdominal cramping, repeated vomiting episodes disrupting daily activities, and malnutrition from inability to properly digest food.

Those suffering intestinal blockages experience excruciating abdominal pain requiring emergency intervention and prolonged recovery periods.

NAION victims cope with sudden, irreversible vision loss transforming their ability to move through the world – reading becomes difficult, driving may become impossible, and facial recognition diminishes.

Ozempic injuries prevent patients from participating in these meaningful life activities:

• Dietary restrictions: Gastroparesis patients often cannot consume normal meals, attend social dining events, or enjoy foods they previously loved
• Physical activities: Intestinal complications may prevent exercise, recreational sports, gardening, or other physical pursuits
• Career limitations: Vision loss from NAION may end careers requiring visual acuity, while chronic nausea disrupts professional performance
• Family relationships: Chronic illness strains marriages and parenting abilities when plaintiffs cannot participate fully in family activities

Loss of consortium claims allow spouses to seek compensation for the ways Ozempic injuries damage marital relationships, including loss of companionship, affection, and sexual relations.

Emotional distress damages address mental health impacts of living with permanent, debilitating conditions caused by a medication that manufacturers allegedly failed to adequately warn about.

Many plaintiffs develop anxiety, depression, or post-traumatic stress from their medical experiences, particularly those who underwent emergency surgeries or suffered permanent vision loss.

Our Ozempic attorney at TruLaw is dedicated to supporting clients through the process of filing an Ozempic lawsuit.

With extensive experience in dangerous drug and pharmaceutical litigation cases, Jessica Paluch-Hoerman and our partner law firms work through the legal process with litigation leaders and medical experts to prove how Ozempic (semaglutide) injections caused you harm.

TruLaw focuses on securing compensation for medical expenses, hospitalization costs, lost wages, pain and suffering, and other damages resulting from your Ozempic-related injuries including gastroparesis, intestinal blockages, gallbladder issues, and other severe gastrointestinal complications.

We understand the physical and emotional toll that Ozempic complications have on your life and provide the personalized guidance you need when seeking justice.

Meet the Lead Ozempic Attorney at TruLaw

Meet our lead Ozempic attorney:

• Jessica Paluch-Hoerman: As founder and managing attorney of TruLaw, Jessica brings her experience in pharmaceutical litigation and personal injury to her client-centered approach by prioritizing open communication and personalized attention with her clients. Through TruLaw and partner law firms, Jessica has helped collect over $3 billion on behalf of injured individuals across all 50 states through verdicts and negotiated settlements.

How much does hiring an Ozempic lawyer from TruLaw cost?

At TruLaw, we believe financial concerns should never stand in the way of justice, which is why we offer a free consultation to evaluate your case.

That’s why we operate on a contingency fee basis – with this approach, you only pay legal fees after you’ve been awarded compensation for your injuries.

If you or a loved one experienced severe gastrointestinal complications, gastroparesis, intestinal blockages, gallbladder problems, or other serious health issues after using Ozempic for diabetes management or weight loss, you may be eligible to file an active lawsuit seeking compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation and determine whether you qualify to join others in filing an Ozempic lawsuit today.

Ozempic lawsuits are being filed by individuals across the country who suffered severe gastrointestinal complications and other serious health problems after using the diabetes and weight-loss medication.

TruLaw is currently accepting clients for the Ozempic lawsuit.

A few reasons to choose TruLaw for your Ozempic lawsuit include:

• If We Don’t Win, You Don’t Pay: The Ozempic lawyers at TruLaw and our partner firms operate on a contingency fee basis, meaning we only get paid if you win.
• Expertise: We have decades of experience handling dangerous drugs cases similar to the Ozempic lawsuit.
• Successful Track Record: TruLaw and our partner law firms have helped our clients recover billions of dollars in compensation through verdicts and negotiated settlements.

If you or a loved one developed gastroparesis, intestinal blockages, gallbladder problems, persistent vomiting, or other severe gastrointestinal complications after using Ozempic for diabetes management or weight loss, you may be eligible to seek compensation.

Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify to join others in filing an Ozempic lawsuit today.